Genetic sequence variant (GSV) in TERT-CLPTM1L (5p15.33 locus) and survival in platinum-treated stage-IV non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Azad, Abul Kalam
Qiu, Xiaoping
Cuffe, Sinead
Qiu, Xin
Boyd, Kevin
Kuang, Qin
Emami, Marjan
Perera, Nicole
Palepu, Prakruthi R.
Patel, Devalben
Chen, Zhuo
Cheng, Dangxiao
Feld, Ronald
Leighl, Natasha B.
Shepherd, Frances A.
Tsao, Ming Sound
Xu, Wei
Liu, Geoffrey
机构：
[1] Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M4X 1K9, Canada
[2] Wuhan Univ, Sch Med, Wuhan, Hubei, Peoples R China
[3] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada
[4] Univ Toronto, Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1535
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The nuclear factor kB (NFkB) and Notch signaling pathways and BRCA1 mRNA expression in stage IV non-small cell lung cancer (NSCLC) patients (p).
    Santarpia, M.
    Sanchez-Ronco, M.
    Magri, I.
    Viteri, S.
    Costa, C.
    Gasco, A.
    Gonzalez Cao, M.
    Mederos, N.
    Salazar, F.
    Bertran-Alamillo, J.
    Capitan, A. Gimenez
    Altavilla, G.
    Benlloch, S.
    Yeste, Z.
    Aldeguer, E.
    Taron, M.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Paclitaxel (P) (day 1 and 8) and carboplatin (C) given on every 3 weeks in advanced (stage III-IV) non-small cell lung cancer (NSCLC).
    Yumuk, PF
    Turhal, NS
    Gumus, M
    Hatabay, NF
    Turken, O
    Ozkan, A
    Salepci, T
    Aliustaoglu, M
    Ekenel, M
    Ahiskali, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 696S - 696S
  • [33] Excision cross-complementing group 1 (ERCC1) single nucleotide polymorphisms (SNPs) and survival in cisplatin (cis)/docetaxel (doc)-treated stage IV non-small cell lung cancer (NSCLC) patients (p):: A Spanish Lung Cancer Group study.
    Taron, M.
    Alberola, V.
    Vivanco, G. Lopez
    Camps, C.
    De las Peñas, R.
    Alonso, G.
    Provencio, M.
    Salvatierra, A.
    Sanchez, J.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 377S - 377S
  • [34] Comparison of patient outcomes stratified by histology among pemetrexed (P)-treated patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) in two phase II trials
    Peng, G.
    Zinner, R. G.
    Wang, Y.
    Treat, J.
    Monberg, M.
    Obasaju, C. K.
    Herbst, R. S.
    Novello, S.
    Scagliotti, G. V.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis
    Schad, Friedemann
    Thronicke, Anja
    Steele, Megan L.
    Merkle, Antje
    Matthes, Burkhard
    Grah, Christian
    Matthes, Harald
    PLOS ONE, 2018, 13 (08):
  • [36] Correlation of radiomic features with PD-L1 expression in early stage non-small cell lung cancer (ES-NSCLC) to predict recurrence and overall survival (OS).
    Patil, Pradnya Dinkar
    Bera, Kaustav
    Vaidya, Pranjal
    Prasanna, Prateek
    Khunger, Monica
    Khunger, Arjun
    Velcheti, Vamsidhar
    Madabhushi, Anant
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] FIRST-LINE MAINTENANCE (1L MT) TREATMENT OF STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC) IN WESTERN EUROPE (WE): RESULTS OF THE CANCERMPACT® SURVEY 2020
    Clark, O.
    Kanas, G.
    Kalilani, L.
    Durbin, L.
    Nersesyan, K.
    Keeven, K.
    Giove, T. J.
    Chao, J.
    Aziez, A.
    Hogea, C.
    Stojadinovic, A.
    VALUE IN HEALTH, 2022, 25 (01) : S156 - S156
  • [38] Overall Survival and Progression Free Survival Results for a Randomized Phase 2 Trial of Ipilimumab (IPI) and Paclitaxel/Carboplatin (P/C) in First-Line Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
    Lynch, T. J.
    Neal, J.
    Bondarenko, I.
    Luft, A.
    Serwatowski, P.
    Barlesi, F.
    Chacko, R.
    Sebastian, M.
    Cuillerot, J.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S515 - S515
  • [39] Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)
    Barlesi, F.
    Ozguroglu, M.
    Vansteenkiste, J. F.
    Spigel, D.
    Yang, J. C-H.
    Bajars, M.
    Ruisi, M.
    Manitz, J.
    Park, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] DNA repair components modulating the function of breast cancer susceptibility gene 1 (BRCA1) in advanced non-small cell lung cancer (NSCLC) patients (p) treated with platinum-based chemotherapy.
    Bonanno, Laura
    Costa, Carlota
    Majem, Margarita
    Javier Sanchez, Jose
    Capitan, Ana Gimenez
    Vergnenegre, Alain
    Massuti, Bartomeu
    Mayo, Clara
    Molina-Vila, Miguel Angel
    Favaretto, Adolfo G.
    Pallares, Cinta
    Benlloch, Susana
    Rugge, Massimo
    Taron, Miquel
    Rosell, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345